{"id":57056,"date":"2026-02-13T12:49:46","date_gmt":"2026-02-13T04:49:46","guid":{"rendered":"https:\/\/flcube.com\/?p=57056"},"modified":"2026-02-13T12:49:47","modified_gmt":"2026-02-13T04:49:47","slug":"amgens-uplizna-wins-european-approval-for-generalized-myasthenia-gravis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57056","title":{"rendered":"Amgen\u2019s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis"},"content":{"rendered":"\n<p><strong>Amgen Inc.<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/AMGN:NASDAQ\">NASDAQ:\u202fAMGN<\/a><\/strong>) announced that the <strong>European Commission (EC)<\/strong> has approved <strong>UPLIZNA (inebilizumab)<\/strong> as an <strong>add-on therapy<\/strong> for <strong>adults with generalized myasthenia gravis (gMG)<\/strong> who are <strong>anti-acetylcholine receptor (AChR)<\/strong> or <strong>anti-muscle specific tyrosine kinase (MuSK) antibody positive<\/strong>. The <strong>humanized monoclonal antibody<\/strong>, which <strong>selectively depletes CD19+ B cells<\/strong> driving autoantibody production, becomes the <strong>first biologic approved in Europe<\/strong> with <strong>demonstrated efficacy in both AChR+ and MuSK+ subtypes<\/strong> and <strong>structured steroid-tapering protocol<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Amgen Inc. (NASDAQ:\u202fAMGN)<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>European Commission (EC)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>UPLIZNA (inebilizumab) \u2013 Humanized anti-CD19 monoclonal antibody<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Generalized myasthenia gravis (gMG) \u2013 AChR+ or MuSK+ adults<\/td><\/tr><tr><td><strong>Treatment Position<\/strong><\/td><td>Add-on to standard therapy<\/td><\/tr><tr><td><strong>US Status<\/strong><\/td><td>Approved April\u202f2025; first and only CD19-targeting therapy for gMG<\/td><\/tr><tr><td><strong>EU Significance<\/strong><\/td><td><strong>First biologic with MuSK+ efficacy data<\/strong>; <strong>structured steroid-tapering protocol<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-disease-amp-mechanism\">Target Disease &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>gMG Profile<\/th><th>UPLIZNA Mechanism<\/th><\/tr><\/thead><tbody><tr><td><strong>Disease Type<\/strong><\/td><td>Rare, chronic, <strong>B-cell-mediated autoimmune disease<\/strong><\/td><td>\u2013<\/td><\/tr><tr><td><strong>Core Symptoms<\/strong><\/td><td>Fluctuating muscle weakness; fatigue; respiratory compromise<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Autoantibody Targets<\/strong><\/td><td><strong>AChR (80% of patients)<\/strong> or <strong>MuSK (5-8%)<\/strong><\/td><td>\u2013<\/td><\/tr><tr><td><strong>UPLIZNA Target<\/strong><\/td><td><strong>CD19+ B cells<\/strong> (including plasmablasts and some plasma cells)<\/td><td><strong>Targeted depletion<\/strong> of autoantibody-producing cells<\/td><\/tr><tr><td><strong>Clinical Impact<\/strong><\/td><td>Improved muscle strength; reduced exacerbations; <strong>steroid-sparing<\/strong><\/td><td><strong>Sustained B-cell depletion<\/strong> with <strong>quarterly maintenance dosing<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-mint-phase-3-study\">Clinical Evidence \u2013 MINT Phase 3 Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study Design<\/th><th>MINT (Myasthenia Gravis Inebilizumab Trial)<\/th><th>Strategic Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Scale<\/strong><\/td><td><strong>Largest Phase 3 biologic study<\/strong> in gMG including <strong>both AChR+ and MuSK+ patients<\/strong><\/td><td><strong>First MuSK+ efficacy demonstration<\/strong> for any biologic<\/td><\/tr><tr><td><strong>Steroid Tapering<\/strong><\/td><td><strong>Structured protocol<\/strong>: Week 4 initiation \u2192 5mg prednisone by Week 24<\/td><td><strong>First successful steroid-sparing study design<\/strong> in gMG<\/td><\/tr><tr><td><strong>Tapering Success<\/strong><\/td><td><strong>87.4% UPLIZNA<\/strong> vs. <strong>84.6% placebo<\/strong> achieved \u22645mg prednisone by Week 26<\/td><td><strong>Steroid reduction achievable<\/strong> with <strong>UPLIZNA add-on<\/strong><\/td><\/tr><tr><td><strong>Efficacy<\/strong><\/td><td><strong>Significant improvement<\/strong> in Myasthenia Gravis-Activities of Daily Living (MG-ADL) scores<\/td><td><strong>Clinically meaningful functional improvement<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-market-context\">Strategic Positioning &amp; Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>gMG Market Size<\/strong><\/td><td><strong>~150,000 patients in Europe<\/strong>; <strong>~60,000 in US<\/strong>; <strong>high unmet need<\/strong> for <strong>steroid-sparing, targeted therapies<\/strong><\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td><strong>Eculizumab (Soliris, Alexion)<\/strong> \u2013 C5 inhibitor, AChR+ only; <strong>Ravulizumab (Ultomiris)<\/strong> \u2013 AChR+ only; <strong>Efgartigimod (Vyvgart, argenx)<\/strong> \u2013 FcRn inhibitor, AChR+ only; <strong>UPLIZNA \u2013 ONLY biologic with MuSK+ data<\/strong><\/td><\/tr><tr><td><strong>MuSK+ Differentiation<\/strong><\/td><td><strong>MuSK+ patients<\/strong> have <strong>poorer prognosis<\/strong>, <strong>limited treatment options<\/strong>; <strong>UPLIZNA addresses underserved population<\/strong><\/td><\/tr><tr><td><strong>Steroid-Sparing Value<\/strong><\/td><td><strong>Chronic corticosteroid toxicity<\/strong> (osteoporosis, diabetes, infection) drives <strong>patient and payer preference<\/strong> for <strong>tapering protocols<\/strong><\/td><\/tr><tr><td><strong>Amgen Rare Disease Strategy<\/strong><\/td><td>UPLIZNA complements <strong>Tepezza (thyroid eye disease)<\/strong> and <strong>Krystexxa (gout)<\/strong>; <strong>B-cell depletion platform<\/strong> expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-amp-expansion-outlook\">Commercial &amp; Expansion Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Priority<\/th><th>Execution Plan<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>EU Launch<\/strong><\/td><td>Market access negotiations; neurology specialist education<\/td><td>Q1-Q2\u202f2026<\/td><\/tr><tr><td><strong>Global Expansion<\/strong><\/td><td>Japan PMDA submission; China NMPA pathway evaluation<\/td><td>2026-2027<\/td><\/tr><tr><td><strong>Label Expansion<\/strong><\/td><td>Potential earlier-line use; combination with other immunotherapies<\/td><td>Post-approval<\/td><\/tr><tr><td><strong>Real-World Evidence<\/strong><\/td><td>MINT extension studies; patient registry establishment<\/td><td>Ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding UPLIZNA European commercial launch, MuSK+ market penetration, and competitive dynamics with efgartigimod and ravulizumab in generalized myasthenia gravis. Actual results may differ due to reimbursement negotiation outcomes, physician adoption of CD19-targeting mechanism, and steroid-tapering protocol implementation challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Amgen Inc. (NASDAQ:\u202fAMGN) announced that the European Commission (EC) has approved UPLIZNA (inebilizumab) as an&#8230;<\/p>\n","protected":false},"author":1,"featured_media":57059,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[330,912,15,24],"class_list":["post-57056","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-amgen","tag-nasdaq-amgn","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Amgen\u2019s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Amgen Inc. (NASDAQ:\u202fAMGN) announced that the European Commission (EC) has approved UPLIZNA (inebilizumab) as an add-on therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. The humanized monoclonal antibody, which selectively depletes CD19+ B cells driving autoantibody production, becomes the first biologic approved in Europe with demonstrated efficacy in both AChR+ and MuSK+ subtypes and structured steroid-tapering protocol.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57056\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen\u2019s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis\" \/>\n<meta property=\"og:description\" content=\"Amgen Inc. (NASDAQ:\u202fAMGN) announced that the European Commission (EC) has approved UPLIZNA (inebilizumab) as an add-on therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. The humanized monoclonal antibody, which selectively depletes CD19+ B cells driving autoantibody production, becomes the first biologic approved in Europe with demonstrated efficacy in both AChR+ and MuSK+ subtypes and structured steroid-tapering protocol.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57056\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-13T04:49:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-13T04:49:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1301.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57056#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57056\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Amgen\u2019s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis\",\"datePublished\":\"2026-02-13T04:49:46+00:00\",\"dateModified\":\"2026-02-13T04:49:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57056\"},\"wordCount\":480,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57056#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1301.webp\",\"keywords\":[\"Amgen\",\"NASDAQ: AMGN\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57056#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57056\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57056\",\"name\":\"Amgen\u2019s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57056#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57056#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1301.webp\",\"datePublished\":\"2026-02-13T04:49:46+00:00\",\"dateModified\":\"2026-02-13T04:49:47+00:00\",\"description\":\"Amgen Inc. (NASDAQ:\u202fAMGN) announced that the European Commission (EC) has approved UPLIZNA (inebilizumab) as an add-on therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. The humanized monoclonal antibody, which selectively depletes CD19+ B cells driving autoantibody production, becomes the first biologic approved in Europe with demonstrated efficacy in both AChR+ and MuSK+ subtypes and structured steroid-tapering protocol.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57056#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57056\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57056#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1301.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1301.webp\",\"width\":1080,\"height\":608,\"caption\":\"Amgen\u2019s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57056#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amgen\u2019s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Amgen\u2019s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry","description":"Amgen Inc. (NASDAQ:\u202fAMGN) announced that the European Commission (EC) has approved UPLIZNA (inebilizumab) as an add-on therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. The humanized monoclonal antibody, which selectively depletes CD19+ B cells driving autoantibody production, becomes the first biologic approved in Europe with demonstrated efficacy in both AChR+ and MuSK+ subtypes and structured steroid-tapering protocol.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57056","og_locale":"en_US","og_type":"article","og_title":"Amgen\u2019s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis","og_description":"Amgen Inc. (NASDAQ:\u202fAMGN) announced that the European Commission (EC) has approved UPLIZNA (inebilizumab) as an add-on therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. The humanized monoclonal antibody, which selectively depletes CD19+ B cells driving autoantibody production, becomes the first biologic approved in Europe with demonstrated efficacy in both AChR+ and MuSK+ subtypes and structured steroid-tapering protocol.","og_url":"https:\/\/flcube.com\/?p=57056","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-13T04:49:46+00:00","article_modified_time":"2026-02-13T04:49:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1301.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57056#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57056"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Amgen\u2019s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis","datePublished":"2026-02-13T04:49:46+00:00","dateModified":"2026-02-13T04:49:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57056"},"wordCount":480,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57056#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1301.webp","keywords":["Amgen","NASDAQ: AMGN","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57056#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57056","url":"https:\/\/flcube.com\/?p=57056","name":"Amgen\u2019s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57056#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57056#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1301.webp","datePublished":"2026-02-13T04:49:46+00:00","dateModified":"2026-02-13T04:49:47+00:00","description":"Amgen Inc. (NASDAQ:\u202fAMGN) announced that the European Commission (EC) has approved UPLIZNA (inebilizumab) as an add-on therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. The humanized monoclonal antibody, which selectively depletes CD19+ B cells driving autoantibody production, becomes the first biologic approved in Europe with demonstrated efficacy in both AChR+ and MuSK+ subtypes and structured steroid-tapering protocol.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57056#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57056"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57056#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1301.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1301.webp","width":1080,"height":608,"caption":"Amgen\u2019s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57056#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Amgen\u2019s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1301.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57056"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57056\/revisions"}],"predecessor-version":[{"id":57060,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57056\/revisions\/57060"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57059"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}